Piling up the JNK: Drug synergy through ER stress

Cancer Biology and Therapy

Volumn 8, Issue 9, 2009, Pages 820-822

  Hertan, Lauren M ^a   Koumenis, Constantinos ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antagonist; Apoptosis; Bcl 2; Caspase 4; eIF2 ; Endoplasmic reticulum; HA14 1; JNK; PERK; Proteasome inhibitor

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; REACTIVE OXYGEN METABOLITE; SALINOSPORAMIDE A; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER RESISTANCE; CANCER SURVIVAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; HUMAN; MULTIPLE MYELOMA; NOTE; OXIDATIVE STRESS; QUALITY OF LIFE;

EID: 68149099778     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.9.8403     Document Type: Note

References (26)

1. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-75.
2. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98.
3. Manochankian R, Miller K, Chanan-Khan A. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist 2007; 12:978-90.
4. O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survival compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 2009; 145:34-9.
5. Mitchell BS. The proteasome-an emerging therapeutic target in cancer. N Engl J Med 2003; 348:2597-8.
6. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in cancer cells. Cancer Res 2006; 66:3773-81.
7. Linder S, Shoshan MC. Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy. Drug Resist Updat 2005; 8:199-204.
8. Fels DR, Ye J, Segan A, Kridel S, Spiotto M, Olson M, et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 2008; 68:9323-30.
9. Benz EJ Jr, Nathan DG, Amaravadi RK, Danial NN. Targeting the cell death-survival equation. Clin Cancer Res 2007; 13:7250-3.
10. Fribley A, Wang C. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006; 5:808-19.
11. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67:1783-92.
12. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshim T, Richardson P, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008; 111:1654-64.
13. Chauhan D, Hideshim T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anti-cancer therapy. Br J Cancer 2006; 95:961-5.
14. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97:7124-9.
15. Marzo I, Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 2008; 76:939-46.
16. Srimatkandada P, Loomis R, Carbone R, Srimatkandada S, Lacy J. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases. Eur J Haematol 2008; 80:407-18.
17. Horton TM, Gannavarpu A, Blaney S, D'Argenio D, Plon S, Berg S. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006; 58:13-23.
18. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28:607-12.
19. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003; 17:2036-45.
20. Lezoualc'h F, Sagara Y, Holsboer F, Behl C. High constitutive NFkappaB activity mediates resistance to oxidative stress in neuronal cells. J Neurosci 1998; 18:3224-32.
21. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NFkappaB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-47.
22. Doshi J, Tian D, Xing C. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2- oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. Mol Pharm 2007; 4:919-28.
23. Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, et al. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther 2009; 8:721-32.
24. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8:519-29.
25. Wu Y, Fabritius M, Ip C. Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer. Cancer Biol Ther 2009; 8:146-52.
26. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7:1648-62.